Clinical trial news

Scholar Rock financing

The biotech Scholar Rock has obtained $47 million in new financing to move its spinal muscular atrophy therapy SRK-015 into clinical trials during the first half of 2018. Invus led the financing round, which included Redmile Group and a number of other investors. “We are delighted by the strong…

play date with friend

The U.S. Food and Drug Administration (FDA) has given AveXis the green light to launch a Phase 1 study of its gene therapy, AVXS-101, in children with spinal muscular atrophy (SMA) Type 2. In contrast to the company’s earlier study in Type 1 SMA children, who received the treatment intravenously,…

muscle activator CK-2127107

Cytokinetics’ new muscle activator compound shows promising safety, tolerability, and effectiveness in three early clinical trials in healthy volunteers. The data supports the ongoing Phase 2 trial of the drug in patients with spinal muscular atrophy. Importantly, the findings indicate that the therapy is better tolerated and more potent than the company’s earlier muscle activator, tirasemtiv. CK-212 7107 is an investigational next-generation therapy that Cytokinetics is developing in collaboration with Astellas Pharma. The compound aims to act as a muscle activator by slowing calcium signaling in so-called fast skeletal muscle fibers. The drug was explored in three separate Phase 1 trials, adding to data from two earlier studies. The studies showed that CK-212 7107 triggered a muscle force more than double of that seen with tirasemtiv. All three trials also concluded that the drug was relatively well tolerated — all adverse events were mild or moderate. Laboratory values, neurological examinations, vital signs, brain waves, walk tests, and blood oxygen levels were all normal after the treatment. Researchers also concluded that higher doses gave rise to higher blood concentrations of the drug — a desirable feature of any new drug. CK-212 7107 is currently being assessed in a Phase 2 trial in patients with SMA types 2–4. The trial is still recruiting participants in the U.S. and Canada. Interested patients can find more information, including contact details, at the trial’s registration page. The drug is intended for the treatment of patients with muscle fatigue or weakness. In addition to SMA, the compound is being tested in Phase 2 trials in patients with ALS, elderly people with mobility limitations, and patients with COPD.

Phase 2 trial of Firdapse

Catalyst Pharmaceuticals is launching a proof-of-concept Phase 2 trial of its investigational drug Firdapse (amifampridine phosphate), intended to relieve symptoms in ambulatory patients with spinal muscular atrophy (SMA) type 3. If the treatment proves effective and safe in this group, which will include about 12 patients, Catalyst plans…